NEUROGENE INC (NGNE)
(Delayed Data from NSDQ)
$42.59 USD
+0.60 (1.43%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $42.60 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NGNE 42.59 +0.60(1.43%)
Will NGNE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NGNE based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for NGNE
Neurogene a new outperform at Baird on gene therapy for Rett syndrome
Neurogene initiated with bullish view at Baird, here's why
Neurogene to Participate in Upcoming Conferences
Neurogene (NGNE) Receives a Buy from TD Cowen
Buy Rating Affirmed: Neurogene’s NGN-401 Poised for Strategic FDA Advancements and Positive Data Release